EMA reviews benefit-risk balance of domperidone

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2013年 / 1448卷 / 1期

关键词：

D O I：

10.1007/s40278-013-2506-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：4 / 4

相关论文

共 50 条

[1] Positive benefit-risk balance for orlistat, finds EMA
Reactions Weekly, 2012, 1390 (1) : 2 - 2
[2] The EMA's CHMP concludes that the benefit-risk balance for MabThera [rituximab] remains positive,
Reactions Weekly, 2012, 1404 (1) : 3 - 3
[3] The EMA confirms that Revlimid's [lenalidomide's] benefit-risk balance remains positive,
Reactions Weekly, 2011, 1371 (1) : 3 - 3
[4] EMA starts new benefit-risk assessment of flupirtine
Reactions Weekly, 2017, 1677 (1) : 2 - 2
[5] Use of Domperidone as a Galactagogue Drug: A Systematic Review of the Benefit-Risk Ratio
Paul, Catherine
Zenut, Marie
Dorut, Agnes
Coudore, Marie-Ange
Vein, Julie
Cardot, Jean-Michel
Balayssac, David
JOURNAL OF HUMAN LACTATION, 2015, 31 (01) : 57 - 63
[6] ASPECTS ON THE BENEFIT-RISK BALANCE OF FELODIPINE IN HYPERTENSION
ELMFELDT, D
WESTERLING, S
DRUGS, 1987, 34 : 132 - 135
[7] CHMP reviews benefit-risk profile of Protelos, Osseor
Reactions Weekly, 2011, 1375 (1) : 2 - 2
[8] NSAIDs: risk of thrombotic events but positive benefit-risk balance
Reactions Weekly, 2006, 1125 (1) : 2 - 2
[9] Amantadine, benefit-risk balance in severe brain injury
Giacino, J. T.
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 4 - 4
[10] Positive benefit-risk balance continues for glitazones – EMEA
Reactions Weekly, 2007, 1175 (1) : 2 - 2

← 1 2 3 4 5 →